|
1
|
Xu H, Wang H, Zhuang L, Yan B, Yu Y, Wei
Z, et al: Demonstration of an anti-oxidative stress mechanism of
quetiapine: implications for the treatment of Alzheimer’s disease.
FEBS J. 275:3718–3728
|
|
2
|
Murray CJL and López AD: The Global Burden
of Disease. Harvard School of Public Health; Boston, MA: 1996
|
|
3
|
Bi X, Zhang Y, Yan B, Fang S, He J, Zhang
D, et al: Quetiapine prevents oligodendrocyte and myelin loss and
promotes maturation of oligodendrocyte progenitors in the
hippocampus of global cerebral ischemia mice. J Neurochem.
123:14–20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fagiolini A, Kupfer DJ, Masalehdan A,
Scott JA, Houck PR and Frank E: Functional impairment in the
remission phase of bipolar disorder. Bipolar Disord. 7:281–285.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sierra P, Livianos L and Rojo L: Quality
of life for patients with bipolar disorder: relationship with
clinical and demographic variables. Bipolar Disord. 7:159–165.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Artigas F: Developments in the field of
antidepressants, where do we go now? Eur Neuropsychopharmacol.
S0924-977X(13)00144-2. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Prieto E, Micó JA, Meana JJ and Majadas S:
Neurobiological bases of quetiapine antidepresant effect in the
bipolar disorder. Actas Esp Psiquiatr. 38:22–32. 2010.PubMed/NCBI
|
|
8
|
Fumagalli F, Molteni R, Bedogni F, et al:
Quetiapine regulates FGF-2 and BDNF expression in the hippocampus
of animals treated with MK-801. Neuroreport. 15:2109–2112. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
López-Muñoz F and Alamo C: Active
metabolites as antidepressant drugs: the role of norquetiapine in
the mechanism of action of quetiapine in the treatment of mood
disorders. Front Psychiatry. 4:1022013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park SW, Lee SK, et al: Effects of
quetiapine on the brain-derived neurotrophic factor expression in
the hippocampus and neocortex of rats. Neurosci Lett. 2:25–29.
2006. View Article : Google Scholar
|
|
11
|
El-Khalili N: Update on extended release
quetiapine fumarate in schizophrenia and bipolar disorders.
Neuropsychiatr Dis Treat. 8:523–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Zhang H, Wang L, Jiang W, Xu H,
Xiao L, et al: Quetiapine enhances oligodendrocyte regeneration and
myelin repair after cuprizone-induced demyelination. Schizophr Res.
138:8–17. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Buckley PF: Efficacy of quetiapine for the
treatment of schizophrenia: a combined analysis of three
placebo-controlled trials. Curr Med Res Opin. 20:1357–1363. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leucht S, Kissling W and Davis JM:
Second-generation antipsychotics for schizophrenia: can we resolve
the conflict? Psychol Med. 39:1591–1602. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Xu H, Jiang W, Xiao L, Yan B, He
J, et al: Quetiapine alleviates the cuprizone-induced white matter
pathology in the brain of C57BL/6 mouse. Schizophr Res.
106:182–191. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhornitsky S, Potvin S, Moteshafi H,
Dubreucq S, Rompré PP and Stip E: Dose-response and comparative
efficacy and tolerability of quetiapine across psychiatric
disorders: a systematic review of the placebo-controlled
monotherapy and add-on trials. Int Clin Psychopharmacol.
26:183–192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grande I, Kapczinski F, Stertz L, Colpo
GD, Kunz M, Cereser KM, et al: Peripheral brain-derived
neurotrophic factor changes along treatment with extended release
quetiapine during acute mood episodes: an open-label trial in
drug-free patients with bipolar disorder. J Psychiatr Res.
46:1511–1514. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bowden CL, Grunze H, Mullen J, Brecher M,
Paulsson B, Jones M, et al: A randomized, double-blind,
placebo-controlled efficacy and safety study of quetiapine or
lithium as monotherapy for mania in bipolar disorder. J Clin
Psychiatry. 66:111–121. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McIntyre RS, Brecher M, Paulsson B, Huizar
K and Mullen J: Quetiapine or haloperidol as monotherapy for
bipolar mania-a 12-week, double-blind, randomised, parallel-group,
placebo-controlled trial. Eur Neuropsychopharmacol. 15:573–585.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshimura R, Ikenouchi-Sugita A, Hori H,
Umene-Nakano W, Katsuki A, Hayashi K, et al: Adding a low dose
atypical antipsychotic drug to an antidepressant induced a rapid
increase of plasma brain-derived neurotrophic factor levels in
patients with treatment-resistant depression. Prog
Neuropsychopharmacol Biol Psychiatry. 34:308–312. 2010. View Article : Google Scholar
|
|
21
|
Vieta E, Suppes T, Eggens I, Persson I,
Paulsson B and Brecher M: Efficacy and safety of quetiapine in
combination with lithium or divalproex for maintenance of patients
with bipolar I disorder (international trial 126). J Affect Disord.
109:251–263. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suppes T, Vieta E, Liu S, Brecher M and
Paulsson B; Trial 127 Investigators. Maintenance treatment for
patients with bipolar I disorder: results from a north american
study of quetiapine in combination with lithium or divalproex
(trial 127). Am J Psychiatry. 166:476–488. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nikisch G, Baumann P, Liu T and Mathé AA:
Quetiapine affects neuropeptide Y and corticotropin-releasing
hormone in cerebrospinal fluid from schizophrenia patients:
relationship to depression and anxiety symptoms and to treatment
response. Int J Neuropsychopharmacol. 15:1051–1061. 2012.
View Article : Google Scholar
|
|
24
|
Bauer M, Pretorius HW, Constant EL, Earley
WR, Szamosi J and Brecher M: Extended-release quetiapine as adjunct
to an antidepressant in patients with major depressive disorder:
results of a randomized, placebo-controlled, double-blind study. J
Clin Psychiatry. 70:540–549. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Weisler R, Joyce M, McGill L, Lazarus A,
Szamosi J and Eriksson H; Moonstone Study Group. Extended release
quetiapine fumarate monotherapy for major depressive disorder:
results of a double-blind, randomized, placebo-controlled study.
CNS Spectr. 14:299–313. 2009.PubMed/NCBI
|
|
26
|
Calabrese JR, Keck PE, Macfadden W Jr,
Minkwitz M, Ketter TA, Weisler RH, et al: A randomized,
double-blind, placebo-controlled trial of quetiapine in the
treatment of bipolar I or II depression. Am J Psychiatry.
162:1351–1360. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thase ME, Macfadden W, Weisler RH, Chang
W, Paulsson B, Khan A, et al: Efficacy of quetiapine monotherapy in
bipolar I and II depression: a double-blind, placebo-controlled
study (the BOLDER II study). J Clin Psychopharmacol. 26:600–609.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Padurariu M, Ciobica A, Dobrin I and
Stefanescu C: Evaluation of antioxidant enzymes activities and
lipid peroxidation in schizophrenic patients treated with typical
and atypical antipsychotics. Neurosci Lett. 479:317–320. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Endicott J, Rajagopalan K, Minkwitz M and
Macfadden W; BOLDER Study Group. A randomized, double-blind,
placebo-controlled study of quetiapine in the treatment of bipolar
I and II depression: improvements in quality of life. Int Clin
Psychopharmacol. 22:29–37. 2007.
|
|
30
|
Endicott J, Paulsson B, Gustafsson U,
Schiöler H and Hassan M: Quetiapine monotherapy in the treatment of
depressive episodes of bipolar I and II disorder: Improvements in
quality of life and quality of sleep. J Affect Disord. 111:306–319.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang K, Delbello M, Chu WJ, Garrett A,
Kelley R, Mills N, et al: Neurometabolite effects of response to
quetiapine and placebo in adolescents with bipolar depression. J
Child Adolesc Psychopharmacol. 22:261–268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dell’Osso B, Arici C, Dobrea C, Benatti B
and Altamura AC: Efficacy, tolerability, compliance, and quality of
life of patients with mood disorders switched from quetiapine
immediate release to extended release. Int Clin Psychopharmacol.
27:310–313. 2012.
|
|
33
|
Connor DF, McLaughlin TJ and Jeffers-Terry
M: Randomized controlled pilot study of quetiapine in the treatment
of adolescent conduct disorder. J Child Adolesc Psychopharmacol.
18:140–156. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kronenberger WG, Giauque AL, Lafata DE,
Bohnstedt BN, Maxey LE and Dunn DW: Quetiapine addition in
methylphenidate treatment-resistant adolescents with comorbid ADHD,
conduct/oppositional-defiant disorder, and aggression: a
prospective, open-label study. J Child Adolesc Psychopharmacol.
17:334–347. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thase ME, Demyttenaere K, Earley WR,
Gustafsson U, Udd M and Eriksson H: Extended release quetiapine
fumarate in major depressive disorder: analysis in patients with
anxious depression. Depress Anxiety. 29:574–586. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Weisler RH, Montgomery SA, Earley WR,
Szamosi J and Lazarus A: Efficacy of extended release quetiapine
fumarate monotherapy in patients with major depressive disorder: a
pooled analysis of two 6-week, double-blind, placebo-controlled
studies. Int Clin Psychopharmacol. 27:27–39. 2012. View Article : Google Scholar
|
|
37
|
Komossa K, Rummel-Kluge C, Schmid F, et
al: Quetiapine versus other atypical antipsychotics for
schizophrenia. Cochrane Database Syst Rev.
1:CD0066252010.PubMed/NCBI
|
|
38
|
Bauer M, El-Khalili N, Datto C, Szamosi J
and Eriksson H: A pooled analysis of two randomised,
placebo-controlled studies of extended release quetiapine fumarate
adjunctive to antidepressant therapy in patients with major
depressive disorder. J Affect Disord. 127:19–30. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liebowitz M, Lam RW, Lepola U, Datto C,
Sweitzer D and Eriksson H: Efficacy and tolerability of extended
release quetiapine fumarate monotherapy as maintenance treatment of
major depressive disorder: a randomized, placebo-controlled trial.
Depress Anxiety. 27:964–976. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Endicott J, Svedsäter H and Locklear JC:
Effects of once-daily extended release quetiapine fumarate on
patient-reported outcomes in patients with generalized anxiety
disorder. Neuropsychiatr Dis Treat. 8:301–311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mezhebovsky I, Mägi K, She F, Datto C and
Eriksson H: Double-blind, randomized study of extended release
quetiapine fumarate (quetiapine XR) monotherapy in older patients
with generalized anxiety disorder. Int J Geriatr Psychiatry.
28:615–625. 2013. View Article : Google Scholar
|
|
42
|
Stein DJ, Bandelow B, Merideth C, et al:
Efficacy and tolerability of extended release quetiapine fumarate
(quetiapine XR) monotherapy in patients with generalised anxiety
disorder: an analysis of pooled data from three 8-week
placebo-controlled studies. Hum Psychopharmacol. 26:614–628. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Merideth C, Cutler AJ, She F and Eriksson
H: Efficacy and tolerability of extended release quetiapine
fumarate monotherapy in the acute treatment of generalized anxiety
disorder: a randomized, placebo controlled and active-controlled
study. Int Clin Psychopharmacol. 27:40–54. 2012. View Article : Google Scholar
|
|
44
|
Khan A, Joyce M, Atkinson S, Eggens I,
Baldytcheva I and Eriksson H: A randomized, double-blind study of
once-daily extended release quetiapine fumarate (quetiapine XR)
monotherapy in patients with generalized anxiety disorder. J Clin
Psychopharmacol. 31:418–428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Van den Eynde F, Senturk V, Naudts K,
Vogels C, Bernagie K, Thas O, et al: Efficacy of quetiapine for
impulsivity and affective symptoms in borderline personality
disorder. J Clin Psychopharmacol. 28:147–155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Perrella C, Carrus D, Costa E and Schifano
F: Quetiapine for the treatment of borderline personality disorder;
an open-label study. Prog Neuropsychopharmacol Biol Psychiatry.
31:158–163. 2007. View Article : Google Scholar
|
|
47
|
Byers MG, Allison KM, Wendel CS and Lee
JK: Prazosin versus quetiapine for nighttime posttraumatic stress
disorder symptoms in veterans: an assessment of long-term
comparative effectiveness and safety. J Clin Psychopharmacol.
30:225–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Savas HA, Yumru M and Ozen ME: Quetiapine
and ziprasidone as adjuncts in treatment-resistant
obsessive-compulsive disorder: a retrospective comparative study.
Clin Drug Investig. 28:439–442. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yatham LN, Kennedy SH, Parikh SV, et al:
Canadian Network for Mood and Anxiety Treatments (CANMAT) and
International Society for Bipolar Disorders (ISBD) collaborative
update of CANMAT guidelines for the management of patients with
bipolar disorder: update 2013. Bipolar Disord. 14:1–44. 2013.
View Article : Google Scholar
|
|
50
|
Kozaric-Kovacic D and Pivac N: Quetiapine
treatment in an open trial in combat-related post-traumatic stress
disorder with psychotic features. Int J Neuropsychopharmacol.
10:253–261. 2007. View Article : Google Scholar
|
|
51
|
Palmer BW, Dawes SE and Heaton RK: What do
we know about neuropsychological aspects of schizophrenia?
Neuropsychol Rev. 19:365–384. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ahearn EP, Mussey M, Johnson C, Krohn A
and Krahn D: Quetiapine as an adjunctive treatment for
post-traumatic stress disorder: an 8-week open-label study. Int
Clin Psychopharmacol. 21:29–33. 2006. View Article : Google Scholar
|
|
53
|
Tandon R, Belmaker RH, Gattaz WF,
Lopez-Ibor JJ, Okasha A, Singh B, et al: World psychiatric
association pharmacopsychiatry section statement on comparative
effectiveness of antipsychotics in the treatment of schizophrenia.
Schizophr Res. 100:20–38. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sokolski KN, Denson TF, Lee RT and Reist
C: Quetiapine for treatment of refractory symptoms of
combat-related post-traumatic stress disorder. Mil Med.
168:486–489. 2003.PubMed/NCBI
|
|
55
|
Torrent C, Martinez-Aran A, Daban C, Amann
B, Balanzá-Martínez V, Del Mar Bonnín C, et al: Effects of atypical
antipsychotics on neurocognition in euthymic bipolar patients.
Compr Psychiatry. 52:613–622. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hamner MB, Deitsch SE, Brodrick PS, Ulmer
HG and Lorberbaum JP: Quetiapine treatment in patients with
posttraumatic stress disorder: an open trial of adjunctive therapy.
J Clin Psychopharmacol. 23:15–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Biskin RS and Paris J: Management of
borderline personality disorder. CMAJ. 184:1897–1902. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Riedel M, Spellmann I, Strassnig M, Douhet
A, Dehning S, Opgen-Rhein M, et al: Effects of risperidone and
quetiapine on cognition in patients with schizophrenia and
predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci.
257:360–370. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Riedel M, Schennach-Wolff R, Musil R,
Dehning S, Cerovecki A, Opgen-Rhein M, et al: Neurocognition and
its influencing factors in the treatment of schizophrenia-effects
of aripiprazole, olanzapine, quetiapine and risperidone. Hum
Psychopharmacol. 25:116–125. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Voruganti LP, Awad AG, Parker G, Forrest
C, Usmani Y, et al: Cognition, functioning and quality of life in
schizophrenia treatment: results of a one-year randomized
controlled trial of olanzapine and quetiapine. Schizophr Res.
96:146–155. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Woodward ND, Purdon SE, Meltzer HY and
Zald DH: A meta-analysis of neuropsychological change to clozapine,
olanzapine, quetiapine, and risperidone in schizophrenia. Int J
Neuropsychopharmacol. 8:457–472. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Bilder RM, Goldman RS, Volavka J, Czobor
P, et al: Neurocognitive effects of clozapine, olanzapine,
risperidone, and haloperidol in patients with chronic schizophrenia
or schizoaffective disorder. Am J Psychiatry. 159:1018–1028. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Harvey PD, Patterson TL, Potter LS, Zhong
K and Brecher M: Improvement in social competence with short-term
atypical antipsychotic treatment: a randomized, double-blind
comparison of quetiapine versus risperidone for social competence,
social cognition, and neuropsychological functioning. Am J
Psychiatry. 163:1918–1925. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Robles O, Zabala A, Bombín I, Parellada M,
Moreno D, Ruiz-Sancho A, et al: Cognitive efficacy of quetiapine
and olanzapine in early-onset first-episode psychosis. Schizophr
Bull. 37:405–415. 2011. View Article : Google Scholar :
|
|
65
|
Van den Eynde F, De Saedeleer S, Naudts K,
Day J, Vogels C, van Heeringen C, et al: Quetiapine treatment and
improved cognitive functioning in borderline personality disorder.
Hum Psychopharmacol. 24:646–649. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gvirts HZ, Harari H, Braw Y, Shefet D,
Shamay-Tsoory SG and Levkovitz Y: Executive functioning among
patients with borderline personality disorder (BPD) and their
relatives. J Affect Disord. 143:261–264. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Dias VV, Balanzá-Martínez V,
Soeiro-de-Souza MG, Moreno RA, Figueira ML, Machado-Vieira R, et
al: Pharmacological approaches in bipolar disorders and the impact
on cognition: a critical overview. Acta Psychiatr Scand.
126:315–331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Harvey PD, Hassman H, Mao L, Gharabawi GM,
Mahmoud RA and Engelhart LM: Cognitive functioning and acute
sedative effects of risperidone and quetiapine in patients with
stable bipolar I disorder: a randomized, double-blind, crossover
study. J Clin Psychiatry. 68:1186–1194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Spielmans GI, Berman MI, Linardatos E,
Rosenlicht NZ, Perry A and Tsai AC: Adjunctive atypical
antipsychotic treatment for major depressive disorder: a
meta-analysis of depression, quality of life, and safety outcomes.
PLoS Med. 10:e10014032013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Asmal L, Flegar SJ, Wang J, et al:
Quetiapine versus other atypical antipsychotics for schizophrenia.
Cochrane Database Syst Rev. 11:CD0066252013.PubMed/NCBI
|
|
71
|
Tohen M, Zarate CA Jr, Hennen J, Khalsa H,
Strakowski SM, Gebre-Medhin P, et al: The McLean-Harvard
First-Episode Mania Study: prediction of recovery and first
recurrence. Am J Psychiatry. 160:2099–2107. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Vigen CL, Mack WJ, Keefe RS, Sano M,
Sultzer DL, Stroup TS, et al: Cognitive effects of atypical
antipsychotic medications in patients with Alzheimer’s disease:
outcomes from CATIE-AD. Am J Psychiatry. 168:831–819. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ekman M, Lindgren P, Miltenburger C, Meier
G, Locklear JC and Chatterton ML: Cost effectiveness of quetiapine
in patients with acute bipolar depression and in maintenance
treatment after an acute depressive episode. Pharmacoeconomics.
30:513–530. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Paleacu D, Barak Y, Mirecky I and Mazeh D:
Quetiapine treatment for behavioural and psychological symptoms of
dementia in Alzheimer’s disease patients: a 6-week, double-blind,
placebo-controlled study. Int J Geriatr Psychiatry. 23:393–400.
2008. View Article : Google Scholar
|
|
75
|
Zarate CA Jr: Antipsychotic drug side
effect issues in bipolar manic patients. J Clin Psychiatry.
61:52–61. 2000.PubMed/NCBI
|
|
76
|
Zhong KX, Tariot PN, Mintzer J, Minkwitz
MC and Devine NA: Quetiapine to treat agitation in dementia: a
randomized, double-blind, placebo-controlled study. Curr Alzheimer
Res. 4:81–93. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Tariot PN, Schneider L, Katz IR, Mintzer
JE, Street J, Copenhaver M, et al: Quetiapine treatment of
psychosis associated with dementia: a double-blind, randomized,
placebo-controlled clinical trial. Am J Geriatr Psychiatry.
14:767–776. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Sajatovic M, Mullen JA and Sweitzer DE:
Efficacy of quetiapine and risperidone against depressive symptoms
in outpatients with psychosis. J Clin Psychiatry. 63:1156–1163.
2002. View Article : Google Scholar
|
|
79
|
Savaskan E, Schnitzler C, Schröder C,
Cajochen C, Müller-Spahn F and Wirz-Justice A: Treatment of
behavioural, cognitive and circadian rest-activity cycle
disturbances in Alzheimer’s disease: haloperidol vs. quetiapine.
Int J Neuropsychopharmacol. 9:507–516. 2006. View Article : Google Scholar
|
|
80
|
Tamayo JM, Zarate CA Jr, Vieta E, Vázquez
G and Tohen M: Level of response and safety of pharmacological
monotherapy in the treatment of acute bipolar I disorder phases: a
systematic review and meta-analysis. Int J Neuropsychopharmacol.
13:813–832. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Cheung G and Stapelberg J: Quetiapine for
the treatment of behavioural and psychological symptoms of dementia
(BPSD): a meta-analysis of randomised placebo-controlled trials. NZ
Med J. 124:39–50. 2011.
|
|
82
|
Miljević Č, Nikolić-Kokić A, Nikolić M,
Niketić V, Spasić MB, Lečić-Toševski D, et al: Effect of atypical
antipsychotics on antioxidant enzyme activities in human
erythrocytes (in vitro study). Hum Psychopharmacol. 28:1–6. 2013.
View Article : Google Scholar
|
|
83
|
LaLonde CD and Van Lieshout RJ: Treating
generalized anxiety disorder with second generation antipsychotics:
a systematic review and meta-analysis. J Clin Psychopharmacol.
31:326–333. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Altamura AC, Serati M, Buoli M and
Dell’Osso B: Augmentative quetiapine in partial/nonresponders with
generalized anxiety disorder: a randomized, placebo-controlled
study. Int Clin Psychopharmacol. 26:201–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wang H, Xu H, Dyck LE and Li X-M:
Olanzapine and quetiapine protect PC12 cells from beta-amyloid
peptide (25–35)-induced oxidative stress and the ensuing apoptosis.
J Neurosci Res. 81:572–580. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Vaishnavi S, Alamy S, Zhang W, Connor KM
and Davidson JR: Quetiapine as monotherapy for social anxiety
disorder: a placebo-controlled study. Prog Neuropsychopharmacol
Biol Psychiatry. 31:1464–469. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Bian Q, Kato T, Monji A, Hashioka S,
Mizoguchi Y, Horikawa H, et al: The effect of atypical
antipsychotics, perospirone, ziprasidone and quetiapine on
microglial activation induced by interferon-gamma. Prog
Neuropsychopharmacol Biol Psychiatry. 32:42–48. 2008. View Article : Google Scholar
|
|
88
|
Tassniyom K, Paholpak S, Tassniyom S and
Kiewyoo J: Quetiapine for primary insomnia: a double blind,
randomized controlled trial. J Med Assoc Thai. 93:729–734.
2010.PubMed/NCBI
|
|
89
|
Kim H, Bang J, Chang HW, Kim JY, Park KU,
Kim SH, et al: Anti-inflammatory effect of quetiapine on
collagen-induced arthritis of mouse. Eur J Pharmacol. 678:55–60.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Potvin S, Morin M, Cloutier C, Gendron A,
Bissonnette A and Marchand S: Add-on treatment of quetiapine for
fibromyalgia: a pilot, randomized, double-blind, placebo-controlled
12-week trial. J Clin Psychopharmacol. 32:684–687. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Luo C, Xu H and Li XM: Quetiapine reverses
the suppression of hippocampal neurogenesis caused by repeated
restraint stress. Brain Res. 1063:32–39. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Hidalgo J, Rico-Villademoros F and
Calandre EP: An open-label study of quetiapine in the treatment of
fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 31:71–77.
2007. View Article : Google Scholar
|
|
93
|
Craig D, Mirakhur A, Hart DJ, McIlroy SP
and Passmore AP: A cross-sectional study of neuropsychiatric
symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr
Psychiatry. 13:460–468. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Schneider LS, Tariot PN, Dagerman KS,
Davis SM, Hsiao JK, Ismail MS, et al: Effectiveness of atypical
antipsychotic drugs in patients with Alzheimer’s disease. N Engl J
Med. 355:1525–1538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Ballard C, Margallo-Lana M, Juszczak E,
Douglas S, Swann A, Thomas A, et al: Quetiapine and rivastigmine
and cognitive decline in Alzheimer’s disease: randomised double
blind placebo controlled trial. BMJ. 330:8742005. View Article : Google Scholar
|
|
96
|
Diniz JB, Shavitt RG, Fossaluza V, et al:
A double-blind, randomized, controlled trial of fluoxetine plus
quetiapine or clomipramine versus fluoxetine plus placebo for
obsessive-compulsive disorder. J Clin Psychopharmacol. 31:763–768.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Bogan AM, Koran LM, Chuong HW, Vapnik T
and Bystritsky A: Quetiapine augmentation in obsessive-compulsive
disorder resistant to serotonin reuptake inhibitors: an open-label
study. J Clin Psychiatry. 66:73–79. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Sevincok L and Topuz A: Lack of efficacy
of low doses of quetiapine addition in refractory
obsessive-compulsive disorder. J Clin Psychopharmacol. 23:448–450.
2003.PubMed/NCBI
|
|
99
|
Denys D, van Megen H and Westenberg H:
Quetiapine addition to serotonin reuptake inhibitor treatment in
patients with treatment-refractory obsessive-compulsive disorder:
an open-label study. J Clin Psychiatry. 63:700–703. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Misri S and Milis L: Obsessive-compulsive
disorder in the postpartum: open-label trial of quetiapine
augmentation. J Clin Psychopharmacol. 24:624–627. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Matsunaga H, Nagata T, Hayashida K, et al:
A long-term trial of the effectiveness and safety of atypical
antipsychotic agents in augmenting SSRI-refractory
obsessive-compulsive disorder. J Clin Psychiatry. 70:863–868. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Maher AR, Maglione M, Bagley S, Suttorp M,
Hu JH, Ewing B, et al: Efficacy and comparative effectiveness of
atypical antipsychotic medications for off-label uses in adults: a
systematic review and meta-analysis. JAMA. 306:1359–1369. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Hirschfeld RMA, Weisler RH, Raines SR and
Macfadden W; BOLDER Study Group. Quetiapine in the treatment of
anxiety in patients with bipolar I or II depression: a secondary
analysis from a randomized, double-blind, placebo-controlled study.
J Clin Psychiatry. 67:355–362. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Cutler AJ, Montgomery SA, Feifel D,
Lazarus A, Aström M and Brecher M: Extended release quetiapine
fumarate monotherapy in major depressive disorder: a placebo- and
duloxetine-controlled study. J Clin Psychiatry. 70:526–539. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
El-Khalili N, Joyce M, Atkinson S, Buynak
RJ, Datto C, Lindgren P, et al: Extended-release quetiapine
fumarate (quetiapine XR) as adjunctive therapy in major depressive
disorder (MDD) in patients with an inadequate response to ongoing
antidepressant treatment: a multicentre, randomized, double-blind,
placebo-controlled study. Int J Neuropsychopharmacol. 13:917–932.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Garakani A, Martinez JM, Marcus S, Weaver
J, Rickels K, Fava M, et al: A randomized, double-blind, and
placebo-controlled trial of quetiapine augmentation of fluoxetine
in major depressive disorder. Int Clin Psychopharmacol. 23:269–275.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
McIntyre A, Gendron A and McIntyre A:
Quetiapine adjunct to selective serotonin reuptake inhibitors or
venlafaxine in patients with major depression, comorbid anxiety,
and residual depressive symptoms: a randomized, placebo-controlled
pilot study. Depress Anxiety. 24:487–494. 2007. View Article : Google Scholar
|
|
108
|
Chaput Y, Magnan A and Gendron A: The
co-administration of quetiapine or placebo to cognitive-behavior
therapy in treatment refractory depression: a preliminary trial.
BMC Psychiatry. 8:732008. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Pascual JC, Soler J, Puigdemont D,
Pérez-Egea R, Tiana T, Alvarez E, et al: Ziprasidone in the
treatment of borderline personality disorder: a double-blind,
placebo-controlled, randomized study. J Clin Psychiatry.
69:603–608. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Schulz SC, Zanarini MC, Bateman A, Bohus
M, Detke HC, Trzaskoma Q, et al: Olanzapine for the treatment of
borderline personality disorder: variable dose 12-week randomised
double-blind placebo-controlled study. Br J Psychiatry.
193:485–492. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Shafti SS and Shahveisi B: Olanzapine
versus haloperidol in the management of borderline personality
disorder: a randomized double-blind trial. J Clin Psychopharmacol.
30:44–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Nickel MK, Muehlbacher M, Nickel C,
Kettler C, Pedrosa Gil F, Bachler E, et al: Aripiprazole in the
treatment of patients with borderline personality disorder: a
double-blind, placebo-controlled study. Am J Psychiatry.
163:833–838. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Allgulander C, Nutt D, Detke M, Erickson
J, Spann M, Walker D, et al: A non-inferiority comparison of
duloxetine and venlafaxine in the treatment of adult patients with
generalized anxiety disorder. J Psychopharmacol (Oxford).
22:417–425. 2008. View Article : Google Scholar
|
|
114
|
Steinberg M and Lyketsos CG: Atypical
antipsychotic use in patients with dementia: managing safety
concerns. Am J Psychiatry. 169:900–906. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Musicco M, Palmer K, Russo A, Caltagirone
C, Adorni F, Pettenati C, et al: Association between prescription
of conventional or atypical antipsychotic drugs and mortality in
older persons with Alzheimer’s disease. Dement Geriatr Cogn Disord.
31:218–214. 2011. View Article : Google Scholar
|
|
116
|
Richter T, Meyer G, Möhler R and Köpke S:
Psychosocial interventions for reducing antipsychotic medication in
care home residents. Cochrane Database Syst Rev.
12:CD0086342012.PubMed/NCBI
|
|
117
|
Ballard Cv and Corbett A: Agitation and
aggression in people with Alzheimer’s disease. Curr Opin
Psychiatry. 26:252–259. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Suppes T, Datto C, et al: Effectiveness of
the extended release formulation of quetiapine as monotherapy for
the treatment of acute bipolar depression. J Affect Disord.
15:485–493. 2014. View Article : Google Scholar
|
